Target Name: ATP6V0A4
NCBI ID: G50617
Other Name(s): VPP2 | V-ATPase subunit a4 | V-ATPase 116 kDa isoform a 4 | V-type proton ATPase 116 kDa subunit a 4 (isoform 4) | ATPase, H+ transporting, lysosomal V0 subunit a isoform 4 | V-type proton ATPase 116 kDa subunit a | A4 | ATP6V0A4 variant 1 | ATPase, H+ transporting, lysosomal V0 subunit a4 | Vacuolar proton pump 116 kDa accessory subunit | ATP6N2 | RTADR | STV1 | VPH1 | ATPase, H+ transporting, lysosomal (vacuolar proton pump) non-catalytic accessory protein 1B | V-ATPase 116 kDa isoform a4 | vacuolar proton pump 116 kDa accessory subunit | VPP4_HUMAN | vacuolar proton pump, subunit 2 | RTA1C | H(+)-transporting two-sector ATPase, noncatalytic accessory protein 1B | ATPase, H+ transporting, lysosomal (vacuolar proton pump) non-catalytic accessory protein 2 (38kD) | ATPase H+ transporting V0 subunit a4, transcript variant 2 | V-ATPase 116 kDa | ATPase H+ transporting V0 subunit a4 | ATPase H+ transporting V0 subunit a4, transcript variant 1 | V-type proton ATPase 116 kDa subunit a isoform 4 | Vacuolar proton pump, subunit 2 | Vacuolar proton translocating ATPase 116 kDa subunit a isoform 4 | DRTA3 | ATP6N1B | ATP6V0A4 variant 2 | RDRTA2 | Vacuolar proton translocating ATPase 116 kDa subunit a kidney isoform

Regulation of CKL3 and Potential Drug/Biomarker Target

ATP6V0A4 (VPP2) is a protein that is expressed in various tissues and cells in the human body. It is a key regulator of the protein kinase CKL3, which is involved in a wide range of cellular processes. In addition to its role in cellular signaling , VPP2 is also a potential drug target and biomarker.

The protein kinase CKL3 is a non-receptor tyrosine kinase (NRTK), which means that it is involved in the regulation of protein kinase activity. CKL3 is a critical regulator of cell signaling, and is involved in the development and maintenance of various cellular processes, including cell growth, differentiation, and survival.

VPP2 is a 21-kDa protein that is expressed in various tissues and cells, including muscle, heart, and brain. It is a key regulator of CKL3, and is involved in the regulation of its activity. VPP2 functions as a negative regulator of CKL3 , which means that it works to decrease the activity of CKL3.

In addition to its role in cellular signaling, VPP2 is also a potential drug target and biomarker. Its involvement in the regulation of CKL3 makes it a potential target for small molecules that can inhibit the activity of CKL3. This could have therapeutic implications for a wide range of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

VPP2 is also a potential biomarker for some diseases. Its expression is often reduced in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This could make it a potential indicator of the severity or stage of these diseases.

In conclusion, ATP6V0A4 (VPP2) is a protein that is involved in the regulation of cellular signaling and has the potential to be a drug target or biomarker. Its role in the regulation of the protein kinase CKL3 makes it a potential target for small molecules, and its expression is often reduced in various diseases, which could make it a potential indicator of the severity or stage of these diseases. Further research is needed to fully understand the role of VPP2 in cellular signaling and its potential as a drug target or biomarker.

Protein Name: ATPase H+ Transporting V0 Subunit A4

Functions: Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (By similarity). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity). Involved in normal vectorial acid transport into the urine by the kidney (PubMed:10973252, PubMed:12414817)

More Common Targets

ATP6V0B | ATP6V0C | ATP6V0CP1 | ATP6V0CP3 | ATP6V0D1 | ATP6V0D1-DT | ATP6V0D2 | ATP6V0E1 | ATP6V0E1P1 | ATP6V0E2 | ATP6V0E2-AS1 | ATP6V1A | ATP6V1B1 | ATP6V1B2 | ATP6V1C1 | ATP6V1C2 | ATP6V1D | ATP6V1E1 | ATP6V1E2 | ATP6V1F | ATP6V1FNB | ATP6V1G1 | ATP6V1G1P1 | ATP6V1G2 | ATP6V1G2-DDX39B | ATP6V1G3 | ATP6V1H | ATP7A | ATP7B | ATP8 | ATP8A1 | ATP8A2 | ATP8B1 | ATP8B1-AS1 | ATP8B2 | ATP8B3 | ATP8B4 | ATP8B5P | ATP9A | ATP9B | ATPAF1 | ATPAF2 | ATPase | ATPSCKMT | ATR | ATRAID | Atrial natriuretic peptide (ANP) receptor | ATRIP | ATRN | ATRNL1 | ATRX | ATXN1 | ATXN10 | ATXN1L | ATXN2 | ATXN2L | ATXN3 | ATXN3L | ATXN7 | ATXN7L1 | ATXN7L2 | ATXN7L3 | ATXN7L3B | ATXN8OS | Augmin | AUH | AUNIP | AUP1 | AURKA | AURKAIP1 | AURKAP1 | AURKB | AURKC | Aurora Kinase | AUTS2 | AVEN | AVIL | AVL9 | AVP | AVPI1 | AVPR1A | AVPR1B | AVPR2 | AWAT1 | AWAT2 | AXDND1 | AXIN1 | AXIN2 | AXL | Axonemal dynein complex | AZGP1 | AZGP1P1 | AZGP1P2 | AZI2 | AZIN1 | AZIN2 | AZU1 | B-cell Antigen Receptor Complex | B2M | B3GALNT1